PL3043785T3 - Zastosowanie R-ketaminy i jej soli jako środków farmaceutycznych - Google Patents

Zastosowanie R-ketaminy i jej soli jako środków farmaceutycznych

Info

Publication number
PL3043785T3
PL3043785T3 PL14793319T PL14793319T PL3043785T3 PL 3043785 T3 PL3043785 T3 PL 3043785T3 PL 14793319 T PL14793319 T PL 14793319T PL 14793319 T PL14793319 T PL 14793319T PL 3043785 T3 PL3043785 T3 PL 3043785T3
Authority
PL
Poland
Prior art keywords
ketamine
pharmaceuticals
salt
application
Prior art date
Application number
PL14793319T
Other languages
English (en)
Inventor
Kenji Hashimoto
Original Assignee
National University Corporation Chiba University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation Chiba University filed Critical National University Corporation Chiba University
Publication of PL3043785T3 publication Critical patent/PL3043785T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL14793319T 2013-09-13 2014-09-12 Zastosowanie R-ketaminy i jej soli jako środków farmaceutycznych PL3043785T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013190066 2013-09-13
PCT/JP2014/004730 WO2015037248A1 (en) 2013-09-13 2014-09-12 Application of r-ketamine and salt thereof as pharmaceuticals
EP14793319.6A EP3043785B1 (en) 2013-09-13 2014-09-12 Application of r-ketamine and salt thereof as pharmaceuticals

Publications (1)

Publication Number Publication Date
PL3043785T3 true PL3043785T3 (pl) 2022-02-28

Family

ID=51846870

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14793319T PL3043785T3 (pl) 2013-09-13 2014-09-12 Zastosowanie R-ketaminy i jej soli jako środków farmaceutycznych

Country Status (15)

Country Link
US (4) US9872841B2 (pl)
EP (2) EP3043785B1 (pl)
JP (6) JP6366439B2 (pl)
CA (2) CA3143962A1 (pl)
CY (1) CY1125290T1 (pl)
DK (1) DK3043785T3 (pl)
ES (1) ES2897453T3 (pl)
HR (1) HRP20211629T1 (pl)
HU (1) HUE056378T2 (pl)
LT (1) LT3043785T (pl)
PL (1) PL3043785T3 (pl)
PT (1) PT3043785T (pl)
RS (1) RS62516B1 (pl)
SI (1) SI3043785T1 (pl)
WO (1) WO2015037248A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
HUE056378T2 (hu) * 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
US20160074340A1 (en) 2014-09-15 2016-03-17 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) * 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
CA3041275A1 (en) 2016-10-27 2018-05-03 National University Corporation Chiba University Pharmaceutical applications for (s)-norketamine and salts thereof
JP2021003001A (ja) * 2017-09-07 2021-01-14 国立大学法人千葉大学 うつ症状の検査方法、及び治療薬のスクリーニング方法
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
WO2019065900A1 (ja) * 2017-09-27 2019-04-04 国立大学法人千葉大学 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
CN117531017A (zh) 2017-12-22 2024-02-09 詹森药业有限公司 用于治疗抑郁症的艾司***
WO2019160057A1 (ja) * 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
EP3813808A4 (en) * 2018-05-04 2022-01-26 Perception Neuroscience, Inc. DRUG TREATMENT METHODS
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
US20220110889A1 (en) * 2018-12-27 2022-04-14 National University Corporation Chiba University R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
CN112125816A (zh) * 2020-03-17 2020-12-25 国药集团工业有限公司 一种***、其衍生物或其盐的消旋化方法
AU2021242363A1 (en) * 2020-03-27 2022-11-03 Homeostasis Therapeutics, Limited Method of treatment for anorexia nervosa, bulimia and related clinical syndromes
CN114306219B (zh) * 2020-09-30 2023-09-26 四川普锐特药业有限公司 稳定的r-***药物组合物
JPWO2022118783A1 (pl) * 2020-12-04 2022-06-09
WO2023064363A1 (en) 2021-10-12 2023-04-20 Perception Neuroscience, Inc. R-ketamine salts and methods of use thereof
WO2023178039A1 (en) 2022-03-14 2023-09-21 Perception Neuroscience, Inc. Pharmaceutical formulations of r-ketamine
CN115006375A (zh) * 2022-06-24 2022-09-06 华中科技大学 艾司***用于制备治疗社交障碍药物的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254124A (en) 1962-06-29 1966-05-31 Parke Davis & Co Aminoketones and methods for their production
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
US4670459A (en) 1984-10-03 1987-06-02 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6382204B1 (en) 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
MXPA02008144A (es) 2000-02-23 2002-11-29 Amgen Inc Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
BRPI0002693B8 (pt) 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7973043B2 (en) 2002-07-30 2011-07-05 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
NZ540282A (en) 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
SI1928405T1 (sl) 2005-09-28 2014-12-31 Auris Medical Ag Farmacevtski sestavki za zdravljenje motenj notranjega ušesa
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) * 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
MX2014010939A (es) 2012-03-12 2014-11-13 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
BR112015003796A2 (pt) 2012-08-23 2017-07-04 L Weg Stuart composição ansiolítica, formulação e método de uso
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
ES2745024T3 (es) 2013-03-15 2020-02-27 Janssen Pharmaceutica Nv Composición farmacéutica de clorhidrato de S-ketamina
WO2014169272A1 (en) 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
EP3094312B1 (en) 2014-01-14 2019-03-13 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
WO2016025581A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
EP3085366A1 (en) 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2019065900A1 (ja) 2017-09-27 2019-04-04 国立大学法人千葉大学 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. DRUG TREATMENT METHODS
US20220110889A1 (en) 2018-12-27 2022-04-14 National University Corporation Chiba University R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
EP3968979A4 (en) 2019-05-15 2023-03-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION

Also Published As

Publication number Publication date
US20220071929A1 (en) 2022-03-10
EP3043785B1 (en) 2021-08-25
CA2923685C (en) 2022-03-08
CA3143962A1 (en) 2015-03-19
JP2020015766A (ja) 2020-01-30
US11207279B2 (en) 2021-12-28
RS62516B1 (sr) 2021-11-30
JP2023011027A (ja) 2023-01-20
JP6842206B2 (ja) 2021-03-17
CA2923685A1 (en) 2015-03-19
CY1125290T1 (el) 2023-03-24
JP6366439B2 (ja) 2018-08-01
JP2024009274A (ja) 2024-01-19
US10406121B2 (en) 2019-09-10
JP2018145207A (ja) 2018-09-20
JP2015078181A (ja) 2015-04-23
WO2015037248A1 (en) 2015-03-19
EP3043785A1 (en) 2016-07-20
SI3043785T1 (sl) 2022-02-28
HRP20211629T1 (hr) 2022-02-04
DK3043785T3 (da) 2021-11-15
LT3043785T (lt) 2021-12-10
ES2897453T3 (es) 2022-03-01
JP2021073310A (ja) 2021-05-13
PT3043785T (pt) 2021-11-05
HUE056378T2 (hu) 2022-02-28
US20180177745A1 (en) 2018-06-28
JP6615277B2 (ja) 2019-12-04
EP3964203A1 (en) 2022-03-09
US20160220513A1 (en) 2016-08-04
US20190343781A1 (en) 2019-11-14
US9872841B2 (en) 2018-01-23
JP7398836B2 (ja) 2023-12-15

Similar Documents

Publication Publication Date Title
LT3043785T (lt) R-ketamino ir jo druskų vartojimas kaip vaistų
HK1254296A1 (zh) 治療性化合物和其用途
IL243608A0 (en) Substances with antiviral activity, preparations containing them and their uses
HK1217092A1 (zh) 治療性化合物及其用途
HK1214255A1 (zh) -醯基氨基噻唑衍生物或其鹽
SG11201507897SA (en) Salt of pyrazoloquinoline derivative, and crystal thereof
IL243614A0 (en) Consequences of mutated pyrazolylpyrazole and its use as a herbicide
PT2967044T (pt) Composição herbicida e seu método de uso
IL243613B (en) Consequences of mutated pyrazolylpyrazole and its use as a herbicide
IL243615A0 (en) Consequences of mutated pyrazolylpyrazole and its use as a herbicide
GB201307233D0 (en) Compounds and uses thereof
HK1219691A1 (zh) 醫藥組成物及其用途
GB201312698D0 (en) Preparation and use of zinc compounds
IL240177A0 (en) Converted chromium-6-yloxy-cycloalkanes and their use as drugs
HK1204916A1 (en) Pharmaceutical application of anhydroicaritin
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
IL240447A0 (en) Propionic-biaryl acid derivatives and their use as pharmaceutical preparations
IL243616A0 (en) Consequences of mutated pyrazolylpyrazole and its use as a herbicide
GB201303476D0 (en) Agrochemical composition and method of use thereof
IL240422B (en) Bi-aryl derivatives of propionic acid and their use as medicinal preparations
EP3052475A4 (en) Pharmaceutical use of 3-benzylsulfonylpropionitrile
AU2013902711A0 (en) Compounds and methods of their use - IV
GB201310349D0 (en) Composition and method of use thereof
GB201301928D0 (en) Composition and method of use thereof